Michel Detheux Sells 43,882 Shares of iTeos Therapeutics, Inc. (NASDAQ:ITOS) Stock

iTeos Therapeutics, Inc. (NASDAQ:ITOS - Get Free Report) CEO Michel Detheux sold 43,882 shares of the firm's stock in a transaction on Friday, June 6th. The stock was sold at an average price of $10.21, for a total value of $448,035.22. Following the sale, the chief executive officer now directly owns 135,903 shares of the company's stock, valued at approximately $1,387,569.63. This trade represents a 24.41% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Michel Detheux also recently made the following trade(s):

• On Friday, June 6th, Michel Detheux sold 8,400 shares of iTeos Therapeutics stock. The stock was sold at an average price of $10.21, for a total value of $85,764.00.
• On Wednesday, June 4th, Michel Detheux sold 43,883 shares of iTeos Therapeutics stock. The stock was sold at an average price of $10.10, for a total value of $443,218.30.
• On Wednesday, June 4th, Michel Detheux sold 8,400 shares of iTeos Therapeutics stock. The stock was sold at an average price of $10.10, for a total value of $84,840.00.

iTeos Therapeutics Trading Down 1.3%

NASDAQ:ITOS traded down $0.13 during midday trading on Monday, reaching $10.04. The company had a trading volume of 1,104,582 shares, compared to its average volume of 661,405. The firm has a market capitalization of $384.27 million, a price-to-earnings ratio of -3.19 and a beta of 1.51. The stock's fifty day simple moving average is $7.38 and its 200-day simple moving average is $7.47. iTeos Therapeutics, Inc. has a 12-month low of $4.80 and a 12-month high of $18.13.

iTeos Therapeutics (NASDAQ:ITOS - Get Free Report) last released its earnings results on Monday, April 28th. The company reported ($0.80) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.94) by $0.14. As a group, sell-side analysts expect that iTeos Therapeutics, Inc. will post -3.49 EPS for the current year.

Analyst Upgrades and Downgrades

Several research firms have issued reports on ITOS. Wells Fargo & Company reissued an "equal weight" rating and set a $12.00 target price (down previously from $13.00) on shares of iTeos Therapeutics in a research note on Wednesday, May 28th. Wedbush cut iTeos Therapeutics from an "outperform" rating to a "neutral" rating and lifted their price objective for the company from $10.00 to $12.00 in a research note on Wednesday, May 28th. HC Wainwright cut iTeos Therapeutics from a "buy" rating to a "neutral" rating in a research note on Wednesday, May 14th. Raymond James set a $12.00 price objective on iTeos Therapeutics in a research note on Wednesday, May 14th. Finally, Piper Sandler reaffirmed an "overweight" rating and issued a $12.00 price objective (down from $16.00) on shares of iTeos Therapeutics in a research note on Wednesday, May 14th. Six equities research analysts have rated the stock with a hold rating and one has given a buy rating to the stock. Based on data from MarketBeat, the company has an average rating of "Hold" and a consensus price target of $15.86.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Strs Ohio purchased a new position in iTeos Therapeutics in the first quarter valued at $31,000. Point72 Asia Singapore Pte. Ltd. purchased a new position in iTeos Therapeutics in the fourth quarter valued at $42,000. CWM LLC boosted its holdings in iTeos Therapeutics by 428.7% in the first quarter. CWM LLC now owns 8,554 shares of the company's stock valued at $51,000 after purchasing an additional 6,936 shares during the period. Paloma Partners Management Co purchased a new position in iTeos Therapeutics in the first quarter valued at $65,000. Finally, Dynamic Technology Lab Private Ltd purchased a new position in iTeos Therapeutics in the first quarter valued at $67,000. 97.16% of the stock is currently owned by hedge funds and other institutional investors.

About iTeos Therapeutics

iTeos Therapeutics, Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.